Access here alternative investment news about Sonoma Biotherapeutics Raises $265M To Advance Therapies For Autoimmune, Inflammatory Diseases
Venture Capital

Sonoma Biotherapeutics Raises $265M To Advance Therapies For Autoimmune, Inflammatory Diseases

by geekwire.com posted 1month ago 13 views
Seattle and South San-Francisco based preclinical biotech company Sonoma Biotherapeutics has raised $265 million in new funding, the company announced Wednesday. The funding will be used to advance its programs aiming to treat autoimmune and inflammatory conditions such as rheumatoid arthritis and type 1 diabetes. The company’s approach involves engineering a special type of immune cell, a regulatory T cell, to enhance its therapeutic potential. Such cells can quell an overactive immune system, thereby easing symptoms of disease.

In this article